Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAICS | P22234 | 6/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21575890 | 0.83 | PAICS (0.55) | PAICS | |
| SCHEMBL20340329 | 0.79 | PAICS (0.45) | PAICSLMNA | |
| SCHEMBL21571645 | 0.78 | PAICS (0.55) | PAICS | |
| SCHEMBL21571651 | 0.77 | PAICS (0.38) | PAICSTP53ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL21571672 | 0.76 | PAICS (0.52) | PAICS | |
| SCHEMBL20352090 | 0.73 | PAICS (0.54) | PAICS | |
| SCHEMBL21571656 | 0.72 | PAICS (0.48) | PAICS | |
| SCHEMBL20339077 | 0.71 | PAICS (0.49) | PAICS | |
| SCHEMBL21571661 | 0.71 | PAICS (0.53) | PAICS | |
| SCHEMBL21571641 | 0.70 | PAICS (0.43) | PAICS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961233-B2 | Oxazole derivatives for use in the treatment of cancer | LIFEARC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20190352295-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352295-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | PAICS, CDK12, CDK13 | PAICS 1/4885SLC6A9 3701/4885TP53 406/4885 |
| US-10961233-B2 | Oxazole derivatives for use in the treatment of cancer | PAICS, CDK13, CDK12 | PAICS 1/4885SLC6A9 3592/4885TP53 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.